explore -WSS

explore

author：hotspot 2025-09-29 20:17:21 - browse：62813

NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment.

But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’re eligible. For some patients with especially aggressive cancer, they can die while waiting for the therapy to arrive.

That’s spurred CAR-T manufacturers to find ways to speed up manufacturing. The industry is testing newer — and possibly better — CAR-T cells that can be made more quickly. Researchers working with Novartis presented Phase 1 clinical trial data Sunday on a new CAR-T cell made with a rapid manufacturing process at the annual American Society of Hematology meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Infant mortality in U.S. rose last year for first time in decades: CDC

WSS

Chemotherapy shortages won’t get better under Biden’s latest plan

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

After sickle

Pfizer plans to depart BIO

SCOTUS to consider access to abortion pill mifepristone

Life sciences investors close nearly $6 billion in new funds

leisure time

explore

explore

The cancer drug shortage isn’t new — and neither are the solutions

Life sciences investors close nearly $6 billion in new funds

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Kidney transplant patients stopped immunosuppressants in trial

DIEP, the 'gold standard' of breast reconstruction, is under threat

After Sarepta trial failure, Duchenne families brace for more debate

Alkermes shareholders re

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Hepatitis C has a cure — but many Americans still lack access to it

FDA approves world's first CRISPR

hotspot

FDA approves world's first CRISPR

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

In diabetes hearing, Sanders takes on a new foe: food makers

Why sickle cell disease is getting the first CRISPR treatment

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Gene therapy’s promise and the high cost of hope

hotspot

Wikipedia

explore

leisure time